Literature DB >> 21385183

Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes.

A Schaub1, S von Gunten, M Vogel, S Wymann, M Rüegsegger, B M Stadler, M Spycher, H-U Simon, S Miescher.   

Abstract

BACKGROUND: Intravenous immunoglobulin (IVIG) preparations are increasingly used for the treatment of autoimmune and chronic inflammatory diseases. Naturally occurring autoantibodies against Siglec-9 and Fas are thought to contribute to the anti-inflammatory effects of IVIG via cell death regulation of leukocytes and tissue cells. Dimeric IVIG fractions are suspected to contain idiotypic (Id)-anti-idiotypic complexes of antibodies, which might also include anti-Siglec-9 and anti-Fas autoantibodies.
METHODS: Dimeric IVIG fractions were separated from monomeric IVIG by size-exclusion chromatography and remonomerized by low pH treatment. Binding studies of total, monomeric, and dimeric IVIG were performed using surface plasmon resonance and flow cytometry on primary human neutrophils.
RESULTS: Anti-Siglec-9 and anti-Fas autoantibodies were contained in both monomeric and dimeric IVIG fractions, but anti-Siglec-9 antibodies were highly enriched in dimeric IVIG. The propensity to engage in dimer formation was paratope dependent. IVIG binding to Siglec-9 was specific and sialylation independent. Interestingly, we detected anti-idiotypic antibodies (anti-Ids) against anti-Siglec-9 autoantibodies in dimeric, but not in monomeric fractions of IVIG.
CONCLUSIONS: Our study supports the concept that idiotype-anti-idiotype (Id-anti-Id) interactions contribute to the dimer formation in IVIG preparations. To our knowledge, this is the first description of Id-anti-Id dimers of death receptor-specific antibodies in IVIG. Such Id-anti-Id interactions might determine the activity of immunomodulatory antibodies present both in IVIG and the patient.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385183     DOI: 10.1111/j.1398-9995.2011.02579.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  15 in total

1.  Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.

Authors:  S von Gunten
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

2.  The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites.

Authors:  Christoph Schneider; David F Smith; Richard D Cummings; Kayluz Frias Boligan; Robert G Hamilton; Bruce S Bochner; Sylvia Miescher; Hans-Uwe Simon; Anastas Pashov; Tchavdar Vassilev; Stephan von Gunten
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

Review 3.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

Review 4.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

Review 5.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 6.  Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.

Authors:  Manu Shankar-Hari; Jo Spencer; William A Sewell; Kathryn M Rowan; Mervyn Singer
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

7.  A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms.

Authors:  Sarah Casulli; Selma Topçu; Lakhdar Fattoum; Stephan von Gunten; Hans-Uwe Simon; Jean-Luc Teillaud; Jagadeesh Bayry; Srini V Kaveri; Carole Elbim
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

Review 8.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

Review 9.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

10.  Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.

Authors:  Christian Ritter; Ilja Bobylev; Helmar C Lehmann
Journal:  J Neuroinflammation       Date:  2015-08-14       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.